Novel lipid-lowering peptide derived from probiotic thalli and application of novel lipid-lowering peptide

The lipid-lowering peptides AP7 and TE8 extracted from Lactobacillus plantarum W8 cells have solved the problem of large side effects of existing lipid-lowering drugs, achieving a safe and effective multi-target lipid-lowering effect, and significantly improving lipid metabolism disorders and hepatic steatosis.

CN121949453APending Publication Date: 2026-05-01SHENYANG AGRI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610059074.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-01-16
Publication Date
2026-05-01

AI Technical Summary

Technical Problem

Existing lipid-lowering drugs, such as statins, have side effects such as liver damage and muscle toxicity, and their improvement on lipid metabolism disorders is limited. Finding natural bioactive substances with high safety, few side effects, and multi-target effects has become an important direction, especially lipid-lowering peptides derived from microorganisms, which have shown significant potential.

Method used

A novel lipid-lowering peptide, AP7, and TE8, derived from Lactobacillus plantarum W8, is provided. These peptides bind to bile salts, inhibit cholesterol micelle formation, and inhibit pancreatic lipase and pancreatic cholesterol esterase activity. They can be used to prepare products that improve lipid metabolism disorders, including pharmaceuticals, health supplements, or functional foods.

Benefits of technology

It exhibits significant lipid-lowering activity in in vitro models, effectively inhibiting cholesterol micellar dissolution and key digestive enzyme activity. In animal experiments, it significantly inhibits high-fat diet-induced weight gain and body fat accumulation, improves hepatic steatosis and intestinal mucosal damage, enhances antioxidant defense capabilities, and achieves systemic improvement of lipid metabolism disorders through multi-target synergistic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121949453A_ABST
    Figure CN121949453A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of functional microorganism application, and particularly relates to a novel lipid-lowering peptide derived from a probiotic thallus and application thereof, the novel lipid-lowering peptide is a crushed substance derived from a probiotic lactobacillus plantarum thallus, and the molecular weight of the novel lipid-lowering peptide is less than 3kDa. And two key polypeptides APGFGDR (AP7) and TESGAFGR (TE8) are identified from the components, and can specifically inhibit the activities of pancreatic lipase and pancreatic cholesterol esterase. The extracted thallus peptide can be efficiently combined with cholate to inhibit the formation of cholesterol micelles, and has a remarkable inhibiting effect on pancreatic lipase and pancreatic cholesterol esterase. Animal experiments show that the mycopeptide can effectively improve lipid metabolism disorder induced by high fat diet, inhibit weight gain, reduce serum and liver lipid levels and relieve fatty degeneration and inflammation of the liver. The lipid-lowering peptide disclosed by the invention is high in safety and multi-target in action, and can be used for preparing functional products for preventing or treating metabolic diseases such as obesity, hyperlipidemia and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of functional microbial application technology, and specifically relates to a novel lipid-lowering peptide derived from probiotic cells and its application. Background Technology

[0002] Lipid metabolism disorders are a core issue in the prevention and control of chronic metabolic diseases. Long-term unhealthy lifestyles, such as high-fat diets, disrupt lipid metabolism balance, trigger inflammation and insulin resistance, and significantly increase the risk of obesity, type 2 diabetes, and non-alcoholic fatty liver disease, typically manifested as elevated serum total cholesterol, triglycerides, and low-density lipoprotein cholesterol. The mortality and medical burden caused by these diseases are increasingly heavy, necessitating safe and effective interventions. Existing mainstream lipid-lowering drugs (such as statins) have side effects such as liver damage and muscle toxicity with long-term use, resulting in low patient compliance and limited overall improvement of metabolic disorders. Therefore, finding safe, low-side-effect, and multi-target natural bioactive substances has become an important direction, with natural food-derived, especially microbial-derived, lipid-lowering peptides showing significant potential.

[0003] Among the many microbial sources of peptide production, *Lactobacillus plantarum* (…) Lactiplantibacillus plantarum Due to its GRAS certification and abundant resources, it demonstrates significant advancements and innovative potential. Previous research has found that... Lactiplantibacillus plantarum W8 has lipid-lowering effects and is highly safe with no toxic side effects. Compared with peptides traditionally derived from fermentation supernatants or unstable extraction methods, the active peptides produced by this strain are derived from the bacterial cells themselves, featuring stable sources, ease of preparation, and controllable quality. As an important component of probiotics, these peptides are more secure in terms of safety and are more easily accepted and utilized by the body. Therefore, microbial lipid-lowering peptides derived from *Lactobacillus plantarum* hold promise as a new strategy for replacing or adjuvant treatment of lipid metabolism disorders, further highlighting their research value and application prospects in the health field. Summary of the Invention

[0004] To address the aforementioned technical problems, this invention provides a novel lipid-lowering peptide derived from probiotic cells and its applications.

[0005] This invention is achieved by providing a novel lipid-lowering peptide derived from probiotic cells, wherein the lipid-lowering peptide is AP7 or TE8, the amino acid sequence of AP7 is APGFGDR, and the amino acid sequence of TE8 is TESGAFGR.

[0006] Preferably, the lipid-lowering peptide is extracted and isolated from the cells of Lactiplantibacillus plantarum W8, which is deposited at the China General Microbiological Culture Collection Center with accession number CGMCC No. 31521 and deposit date of August 1, 2024.

[0007] Preferably, Lactobacillus plantarum W8 is isolated from fermented soybean paste.

[0008] Preferably, the molecular weight of the lipid-lowering peptide is less than 3 kDa.

[0009] The application of the novel lipid-lowering peptide derived from probiotic cells is provided, namely, its use in the preparation of products that improve lipid metabolism disorders.

[0010] Preferably, the improvement of lipid metabolism disorder includes one or more of the following: binding bile salts, inhibiting cholesterol micelle formation, reducing serum total cholesterol, reducing serum triglycerides, reducing serum low-density lipoprotein cholesterol, increasing serum high-density lipoprotein cholesterol, reducing hepatic lipid deposition, alleviating hepatic steatosis, reducing weight gain, reducing body fat accumulation, improving oxidative stress, or inhibiting inflammation.

[0011] Another application of the novel lipid-lowering peptide derived from probiotic cells is provided for the preparation of products that inhibit pancreatic lipase and / or pancreatic cholesterol esterase.

[0012] A product is provided for improving lipid metabolism disorders or inhibiting pancreatic lipase and / or pancreatic cholesterol esterase, the product comprising the aforementioned lipid-lowering peptides.

[0013] Preferably, the product is a drug, health product, or functional food.

[0014] Compared with the prior art, the present invention has the following technical effects: 1. A small-molecule bioactive peptide fraction with a molecular weight less than 3 kDa was successfully isolated from *Lactobacillus plantarum* W8 cells. It exhibited comprehensive lipid-lowering activity in an in vitro model. This fraction efficiently bound bile salts (with binding rates of up to 60.30%, 55.61%, and 42.47% for sodium cholate, sodium glycocholate, and sodium taurocholate, respectively), inhibited cholesterol micellar dissolution (inhibition rate of 60.66%), and effectively inhibited pancreatic lipase and pancreatic cholesterol esterase activities (inhibition rates of 62.64% and 36.51%, respectively), indicating that it can block dietary lipid absorption through multiple synergistic pathways.

[0015] 2. In animal models, this novel lipid-lowering peptide significantly inhibited high-fat diet-induced weight gain and body fat accumulation, effectively reversed abnormal lipid levels in serum and liver, and improved hepatic steatosis and intestinal mucosal damage. Its mechanism of action involves enhancing the body's antioxidant defense capacity and inhibiting chronic inflammation in the liver and intestines, achieving a systemic improvement of lipid metabolism disorders from multiple targets.

[0016] 3. Through mass spectrometry identification and molecular docking analysis, the polypeptide sequences APGFGDR (AP7) and TESGAFGR (TE8) that can stably bind to the active sites of pancreatic lipase and pancreatic cholesterol esterase were screened from the novel lipid-lowering peptides, revealing at the molecular level their mechanism of exerting lipid-lowering effects by competitively inhibiting key digestive enzymes.

[0017] 4. This invention involves the solid-phase chemical synthesis of preferred peptides AP7 and TE8, and further verification of their functions through in vitro enzyme activity experiments. The results show that AP7 and TE8 are key active ingredients with lipid-lowering potential. Both exhibit potent and comparable inhibitory activity against pancreatic lipase (PL), with inhibition rates of 63.33% and 63.98%, respectively. Simultaneously, both also show clear inhibitory abilities against pancreatic cholesterol esterase (CE), with AP7 showing a stronger inhibitory effect of 56.91%, while TE8's inhibition rate is 43.19%. By simultaneously inhibiting PL and CE, peptides AP7 and TE8 demonstrate their potential as dual-target lipid-lowering agents. Attached Figure Description

[0018] Figure 1 The bile salt binding rate of different components of the active peptide; Figure 2 The cholesterol micelle solubility inhibition rate of different active peptide components; Figure 3 The inhibition rates of pancreatic lipase and pancreatic cholesterol esterase of different active peptide components; Figure 4 The effects of bioactive peptides on body weight and food intake in mice on a high-fat diet; Figure 5 The effect of bioactive peptides on serum liver function indicators in mice fed a high-fat diet; Figure 6 The effect of bioactive peptides on serum lipid levels in mice on a high-fat diet; Figure 7 The effect of bioactive peptides on liver lipid levels in mice on a high-fat diet; Figure 8 The effect of bioactive peptides on liver oxidative stress levels in mice on a high-fat diet; Figure 9 The effect of bioactive peptides on the levels of liver inflammatory factors in mice on a high-fat diet; Figure 10The effect of bioactive peptides on the levels of intestinal inflammatory factors in mice on a high-fat diet; Figure 11 For pathological observation of liver, colon, and epididymal fat in mice; Figure 12 Results of PCPE1 component peptide identification based on LC-MS / MS; Figure 13 Diagram showing the docking of AP7 and CE molecules; Figure 14 Diagram showing the docking of TE8 and CE molecules; Figure 15 Diagram showing the docking of AP7 and PL molecules; Figure 16 This is a diagram showing the docking of TE8 and PL molecules. Detailed Implementation

[0019] The following will describe in detail the implementation methods, product formulations, technical content, objectives, and effects of this application with reference to the accompanying drawings and embodiments.

[0020] Example 1: Preparation method of bioactive peptides from Lactobacillus plantarum W8 1. Preparation of bioactive peptides from Lactobacillus plantarum W8: The preparation of bioactive peptides from *Lactobacillus plantarum* W8 begins with the activation and cell disruption of the bacterial strain: The strain, preserved in glycerol at -80℃, was inoculated into MRS medium for activation. After three generations of streak plating purification, a bacterial suspension was obtained. The bacterial suspension was centrifuged at 8000 rpm for 25 minutes to collect the bacterial cells, which were then washed with PBS buffer and resuspended to prepare a bacterial suspension. Subsequently, the bacterial suspension was homogenized three times under low-temperature, high-pressure conditions at 100 MPa. The resulting lysate was stored at 4℃ for later use.

[0021] 2. Ammonium sulfate precipitation and dialysis desalination Ammonium sulfate was added to both the supernatant and the bacterial cell fragments to achieve a final saturation of 80%, and the mixtures were salted out at 4°C for 12 hours. The precipitates were then collected by centrifugation at 8000 r / min for 20 minutes. The precipitates were dissolved in 10 mmol / L Tris-HCl buffer (pH 7.2), and the solution was transferred to a dialysis bag with a molecular weight cutoff of 1 kDa. The solution was then desalted at 4°C (the dialysis buffer was changed every 4 hours for a total of 4 changes), ultimately yielding crude peptide extracts (SCPE) from the supernatant and (PCPE) from the bacterial cell fragments.

[0022] 3. Ultrafiltration and lyophilization The obtained SCPE and PCPE were ultrafiltered and fractionated using ultrafiltration tubes with molecular cutoffs of 10 kDa and 3 kDa. The fractions with molecular cutoffs of <3 kDa, 3-10 kDa, and >10 kDa were collected. The crude peptide extract and the ultrafiltration fraction were freeze-dried under vacuum to obtain freeze-dried crude peptide samples from different sources. After being aliquoted, they were stored at -80°C for later use.

[0023] Example 2: In vitro lipid-lowering ability of Bacillus plantarum W8 bioactive peptides 1. Active peptide bile salt binding rate Accurately measure 0, 0.1, 0.2, 0.3, 0.4, 0.5, and 0.6 mL of 0.3 mmol / L cholate standard solution (containing sodium cholate, sodium glycocholate, and sodium taurocholate, in 0.1 mol / L phosphate buffer, pH 6.3) into 5 mL centrifuge tubes, and bring the volume to 1 mL with the aforementioned phosphate buffer. Add 3 mL of 60% sulfuric acid solution to each tube, mix well, and react in a 70°C water bath for 30 minutes. Cool to room temperature in an ice-water bath, and measure the absorbance at 387 nm. Plot a standard curve for each cholate with cholate concentration on the x-axis and absorbance on the y-axis. Mix 2 mL of the test sample solution (concentration 5 mg / mL) with 8 mL of cholate standard solution, and use 2 mL of phosphate buffer as a blank control. Incubate the mixture at 37°C with shaking for 2 hours, then centrifuge at 4500 r / min for 20 minutes. Take 1 mL of the supernatant and determine the absorbance as described in 1.1. Calculate the residual bile salt concentration in the supernatant based on the standard curve, and calculate the binding rate using the following formula: Binding rate (%) = (A0 - A1) / A0 × 100 Where A0 is the bile salt concentration in the blank group and A1 is the bile salt concentration in the sample group.

[0024] Measurement results (see) Figure 1 The results indicate that the bile salt binding capacity of somatic peptides (PCPE) is significantly superior to that of supernatant peptides (SCPE). P <0.05), and the binding rates of each SCPE component were all below 15%; the binding ability of different bile salts was in the following order: sodium cholate > sodium glycocholate > sodium taurocholate. Among them, the <3 kDa component derived from bacteria (PCPE1) performed the best, with binding rates of 60.30%, 55.61%, and 42.47% for sodium cholate, sodium glycocholate, and sodium taurocholate, respectively, significantly higher than other components ( P <0.05). The prepared bioactive peptides from *Lactobacillus plantarum* W8 cells, especially the PCPE1 component with a molecular weight <3 kDa, exhibited excellent bile salt binding capacity in vitro, indicating their promising potential for lipid-lowering applications.

[0025] 2. Solubility inhibition rate of active peptide cholesterol micelles Prepare an artificial simulated cholesterol micelle solution with the following composition: 10 mmol / L sodium taurocholate, 2 mmol / L cholesterol, 1 mmol / L oleic acid, 132 mmol / L sodium chloride, and 15 mmol / L sodium phosphate buffer solution (pH 7.4). Use an ultrasonic cell disruptor to process it at a power of 400 W for 40 minutes to fully mix and form uniform micelles. Accurately weigh each test sample and dissolve it in the above cholesterol micelle solution to make its final concentration 5 mg / mL. Place the mixed solution in a constant temperature shaking incubator at 37°C and react for 24 hours, then centrifuge at 8000 r / min for 30 minutes. Collect the supernatant and detect the cholesterol content in it using a total cholesterol (TC) assay kit. Calculate the solubility inhibition rate of cholesterol micelles according to the following formula: Inhibition rate (%) = (C0 - C1) / C_0 × 100 Where C0 is the cholesterol concentration in the initial micelle solution, and C1 is the cholesterol concentration in the supernatant after adding the sample and reacting.

[0026] The experimental results (see Figure 2 ) show that the cell-derived active peptide (PCPE) of Lactiplantibacillus plantarum W8 exhibits significant cholesterol micelle solubility inhibitory activity, which is significantly better than the supernatant-derived active peptide (SCPE), and the latter has weak activity. Among the components of PCPE, there are significant differences in the inhibitory effects (<0.05), and their order of strength is >10 kDa < 3-10 kDa < PCPE as a whole < 3 kDa. Among them, the PCPE-1 component with a molecular weight less than 3 kDa is the most prominent, with an inhibition rate as high as 60.66%. This indicates that the cell-derived active peptide, especially the PCPE-1 component, can reduce the digestion and absorption of cholesterol by the body by effectively inhibiting the solubility of cholesterol micelles, showing good lipid-lowering potential.

[0027] 3. Inhibition rates of active peptides on pancreatic lipase and pancreatic cholesterol esterase The inhibition experiment was carried out by mixing 50 μL of active peptide solution (5 mg / mL), 50 μL of enzyme solution (PL: 3 U / mL or CE: 0.75 U / mL), and 50 μL of PNPB solution (5 mmol / L), and making up the volume to 200 μL with Tris-HCl buffer solution (0.1 mol / L, pH = 7.5) to construct a reaction system.

[0028] Table 1 Reaction system for the inhibitory ability of pancreatic lipase and pancreatic cholesterol esterase Grouping Enzyme (μL) Sample (μL) PNPB (μL) Buffer solution (μL) A 50 - 50 100 B - - 50 150 C 50 50 50 50 D - 50 50 100 ​After incubating the above reaction system at 37°C for 15 min, the absorbance was measured at 405 nm using a microplate reader. The enzyme activity inhibition rate was calculated using the following formula: In the formula, A: control group, B: blank control group, C: sample group, and D: blank sample group.

[0029] Experimental results (see) Figure 3 The results show that the fraction of bioactive peptides derived from *Lactobacillus plantarum* W8 cells with a content less than 3 kDa exhibits outstanding inhibitory activity against lipases. This fraction showed an inhibition rate of up to 62.64% against pancreatic lipase and 36.51% against pancreatic cholesterol esterase, significantly higher than other fractions. This confirms that bioactive peptides with a content less than 3 kDa are the core active ingredient for inhibiting these two key enzymes.

[0030] Example 3: Effect of bioactive peptides derived from *Lactobacillus plantarum* W8 cells on improving lipid metabolism disorders induced by a high-fat diet in mice. 1. Preparation of bioactive peptides <3 kDa derived from *Lactobacillus plantarum* cells PCPE1 is a sample containing bioactive peptides derived from Lactobacillus plantarum W8 cells, with <3 kDa fractions retained.

[0031] 2. Grouping of experimental animals and establishment of a high-fat mouse model Specifically, purchased mice were acclimatized for 7 days before the experiment and then randomly divided into 6 groups (n=7 per group) and labeled with picric acid solution. The groups included: blank control group (NC), high-fat model group (HFD), positive control group (POS), and low (LP1), medium (MP1), and high (HP1) dose active peptide groups. All mice were housed in an SPF-grade environment, maintained at room temperature of 25℃ ± 1℃ and a 12 / 12-hour light / dark cycle, for an experimental period of 8 weeks. During this period, mice were administered via gavage once daily, and their body weight and food intake were recorded. Specific animal groupings and drug dosages are shown in Table 2.

[0032] Table 2 Animal grouping and drug dosage Group Types of feed Gavage medication Dosage (mg / kg·BW) Blank control group ordinary feed PBS - High-fat model group High-fat feed PBS - Positive control group High-fat feed Simvastatin 2.6 Low-dose active peptide group High-fat feed PCPE1 200 Medium-dose active peptide group High-fat feed PCPE1 400 High-dose active peptide group High-fat feed PCPE1 800 3. Effects of bioactive peptides on body weight and food intake in mice on a high-fat diet like Figure 4 As shown, there was no significant difference in food intake among the groups of mice during the experiment. P >0.05), indicating that neither the high-fat diet nor the bioactive peptide intervention affected their normal feeding behavior. Regarding body weight, compared to the blank control group (NC), the high-fat model group (HFD) mice showed a significant increase in body weight ( P<0.05, confirming that the high-fat diet successfully induced an obesity model. Compared with the HFD group, the body weight of each dose of bioactive peptide intervention group was significantly reduced ( P <0.05, in which the body weight of the high-dose group (HP1) decreased to a level that was not significantly different from that of the NC group ( P >0.05). This demonstrates that the active peptide can effectively inhibit body weight gain induced by a high-fat diet without being affected by food intake, and that high-dose PCPE1 (HP1) exhibits the best weight-regulating effect.

[0033] 4. Animal sample collection After the experiment, mice that had been fasted for 16 hours were euthanized by an overdose of isochloroane and subjected to systematic tissue sampling. Blood was collected and serum was separated; major organs such as the heart, liver, spleen, kidney, and colon, as well as multiple adipose tissues, were obtained, washed, weighed, and their organ / fat index was calculated; some tissues were fixed with 10% neutral formalin, while the remaining tissues and serum were flash-frozen in liquid nitrogen and stored at -80°C for subsequent research.

[0034] 5. Determination of organ index and fat coefficient in mice Organ indices and body fat coefficients are important indicators for assessing metabolic disorders. The liver index reflects changes in hepatic fat deposition and metabolic function, while the body fat coefficient assesses the degree of fat accumulation in different areas of the liver. Changes in these indicators are closely related to the development and progression of obesity and related metabolic diseases.

[0035] The experimental results, as shown in Table 3, indicate that compared to the NC group, the liver index of mice in the HFD group increased significantly by 1.28 times. Simultaneously, the abdominal, perirenal, and epididymal fat coefficients increased significantly by 1.88 times, 2.87 times, and 2.87 times, respectively. P <0.05 indicates that the high-fat diet successfully induced a lipid metabolism disorder model. However, there were no significant differences in the heart, kidney, and spleen indices among the experimental groups. P >0.05), indicating that a high-fat diet has a relatively small impact on these organs. Among the different doses of PCPE1 and simvastatin intervention groups, the HP1 group showed the most significant regulatory effect, with its liver index decreasing by 19.95% compared to the HFD group ( P <0.05, and there was no significant difference compared with the NC group ( P >0.05); meanwhile, the abdominal, perirenal, and epididymal fat coefficients in the HP1 group decreased by 40.59%, 54.96%, and 62.65% respectively compared to the HFD group ( P <0.05, and its adjustment effect is significantly better than that of the POS group ( P <0.05, and the abdominal and epididymal fat coefficients were not significantly different from those of the NC group ( P>0.05). High-dose PCPE1 can effectively reverse high-fat diet-induced hepatic lipid accumulation and excessive adipose tissue accumulation, and has a significant ameliorative effect on lipid metabolism disorders.

[0036] Table 3. Effects of bioactive peptides on organ index and fat coefficient in mice on a high-fat diet. NC HFD POS LP1 MP1 HP1 Liver index <![CDATA[4.68±0.06 d ]]> <![CDATA[6.00±0.19 a ]]> <![CDATA[5.30±0.14 c ]]> <![CDATA[5.72±0.21 ab ]]> <![CDATA[5.50±0.16 bc ]]> <![CDATA[4.80±0.07 d ]]> Heart Index <![CDATA[0.27±0.09 a ]]> <![CDATA[0.28±0.09 a ]]> <![CDATA[0.27±0.09 a ]]> <![CDATA[0.28±0.07 a ]]> <![CDATA[0.27±0.09 a ]]> <![CDATA[0.30±0.01 a ]]> Kidney Index <![CDATA[0.97±0.04 a ]]> <![CDATA[0.98±0.03 a ]]> <![CDATA[0.97±0.11 a ]]> <![CDATA[0.96±0.10 a ]]> <![CDATA[0.96±0.12 a ]]> <![CDATA[0.95±0.05 a ]]> Spleen index <![CDATA[0.25±0.01 a ]]> <![CDATA[0.26±0.01 a ]]> <![CDATA[0.26±0.00 a ]]> <![CDATA[0.26±0.02 a ]]> <![CDATA[0.25±0.03 a ]]> <![CDATA[0.26±0.01 a ]]> Abdominal fat percentage <![CDATA[0.64±0.04 d ]]> <![CDATA[1.21±0.09 a ]]> <![CDATA[0.95±0.04 c ]]> <![CDATA[1.10±0.05 b ]]> <![CDATA[0.92±0.03 c ]]> <![CDATA[0.72±0.04 d ]]> Perirenal fat index <![CDATA[0.48±0.03 d ]]> <![CDATA[1.39±0.06 a ]]> <![CDATA[0.90±0.05 b ]]> <![CDATA[1.32±0.09 a ]]> <![CDATA[0.88±0.06 b ]]> <![CDATA[0.62±0.05 c ]]> Epididymal fat index <![CDATA[1.23±0.16 d ]]> <![CDATA[3.54±0.30 a ]]> <![CDATA[1.96±0.16 b ]]> <![CDATA[3.10±0.30 a ]]> <![CDATA[1.71±0.17 bc ]]> <![CDATA[1.32±0.14 cd ]]> Note: Results are expressed as mean ± standard deviation. For comparisons of organ index and fat coefficient of mice in different groups within the same row, different letters indicate significant differences. P <0.05).

[0037] 6. Biochemical index determination Serum samples stored at -80℃ were used to measure liver function indicators (ALT, AST, ALP) and lipid levels (TC, TG, HDL-C, LDL-C) in mice according to the kit instructions. Liver tissue stored at -80℃ was used to prepare tissue homogenates, and liver lipid levels (TC, TG) and liver oxidative stress indicators (T-SOD, GSH-Px, MDA) were measured according to the kit instructions. Liver inflammatory factor levels (TNF-α, IL-6, IL-1β) were measured using ELISA. Colon tissue was used to prepare tissue homogenates, and intestinal inflammatory factor levels (TNF-α, IL-6, IL-1β) were measured using ELISA. Simultaneously, the activities of intestinal barrier function-related indicators (D-LA, DAO) were measured.

[0038] 7. Serum liver function test results To assess the hepatoprotective effect of the described bioactive peptides, key liver function indicators in mouse serum were measured. Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) are important markers for evaluating hepatocellular damage and liver function status. Elevated ALT and AST levels directly reflect impaired hepatocellular membrane integrity or necrosis, while elevated ALP levels are associated with cholestasis and abnormal biliary function.

[0039] The effects of bioactive peptides on the above serum liver function indicators in mice fed a high-fat diet are as follows: Figure 5 As shown. Compared with the blank control group (NC), the serum ALT, AST and ALP levels of mice in the high-fat model group (HFD) were significantly increased. P <0.05%, confirming that a long-term high-fat diet successfully induced liver function damage in mice.

[0040] After PCPE1 intervention, compared with the HFD group, except for the low-dose group (LP1), the serum levels of ALT, AST, and ALP in mice in all other intervention groups were significantly reduced. P<0.05). In particular, high-dose PCPE1 (HP1) showed the most significant improvement: its serum ALP level was significantly lower than that of the positive control group (POS). P <0.05, while serum ALT and AST levels returned to levels that were not statistically different from those in the NC group ( P >0.05). High-dose PCPE1 can effectively reverse abnormal serum liver function indicators caused by a high-fat diet, and has a significant protective and ameliorative effect on hepatocellular damage and liver dysfunction.

[0041] 8. Serum and liver lipid level test results The assessment of lipid metabolism status mainly relies on key indicators such as serum total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). Meanwhile, the pathological accumulation of lipids in non-adipose tissues such as the liver, i.e., ectopic fat deposition, is closely related to the occurrence and development of metabolic syndrome. A long-term high-fat diet is an important factor leading to the aforementioned lipid metabolism disorders. To verify the regulatory effect of the bioactive peptide of this invention, we examined its effect on serum and liver lipid levels in mice on a high-fat diet. The results are as follows... Figure 6 and Figure 7 As shown: Serum lipid levels: Compared with the blank control group (NC), the serum TC, TG, and LDL-C levels of mice in the high-fat diet model group (HFD) were significantly increased by 1.69-fold, 2.37-fold, and 3.96-fold, respectively, while the HDL-C level was significantly decreased by 37.21%. P <0.05%. After PCPE1 intervention, compared with the HFD group, except for the low-dose group (LP1), the serum TC, TG and LDL-C levels in all other groups were significantly reduced ( P <0.05), and HDL-C levels were significantly increased. Among them, high-dose PCPE1 (HP1) showed the most significant effect, with serum TC, TG, and LDL-C levels decreasing by 37.16%, 53.11%, and 72.51% respectively compared to the HFD group, and serum HDL-C levels increasing by 1.57 times. This regulatory effect was superior to the positive control group (POS), and there were no significant differences in any of the indicators compared to the NC group. P >0.05).

[0042] Liver lipid levels: Compared with the NC group, the liver TC and TG levels of mice in the HFD group were significantly increased by 1.97 times and 2.96 times, respectively. P <0.05 indicates severe lipid deposition in the liver. Compared with the HFD group, except for the LP1 group, the levels of TC and TG in the liver of the other intervention groups were significantly reduced ( P<0.05. Among them, the intervention effect of HP1 group was the most significant, with liver TC and TG levels significantly reduced by 45.62% and 53.45%, respectively. TC levels recovered to a level not significantly different from that of NC group, and the reduction in TG levels was significantly better than that of POS group. P <0.05). High-dose PCPE1 can simultaneously and effectively reverse high-fat diet-induced serum lipid abnormalities and ectopic fat deposition in the liver, and has a significant ameliorative effect on systemic and local liver lipid metabolism disorders.

[0043] 9. Results of liver oxidative stress level test Oxidative stress is one of the core pathological features of hepatic lipid metabolism disorders, characterized by decreased antioxidant enzyme activity and accumulation of lipid peroxidation products. To verify the antioxidant capacity of the bioactive peptides of this invention, we examined their effect on oxidative stress levels in the livers of mice on a high-fat diet. The results are as follows: Figure 8 As shown: Compared with the blank control group (NC), the total superoxide dismutase (T-SOD) and glutathione peroxidase (GSH-Px) activities in the liver of high-fat diet (HFD) mice were significantly reduced by 34.89% and 31.23%, respectively. P <0.05%, while the malondialdehyde (MDA) content increased significantly by 2.06 times ( P <0.05 indicates that the liver of the model group mice suffered significant oxidative stress damage. After PCPE1 intervention, compared with the HFD group, except for the low-dose group (LP1), the activities of T-SOD and GSH-Px in the liver of mice in all other intervention groups were significantly increased, and the content of MDA was significantly decreased. P <0.05%. Among them, the intervention effect of high-dose PCPE1 (HP1) was the most significant, with liver T-SOD and GSH-Px activities increasing by 1.55 times and 1.45 times respectively compared with the HFD group, while MDA content decreased by 42.59%, and returned to a level that was not significantly different from that of the NC group. P >0.05). High-dose PCPE1 can improve liver oxidative stress induced by a high-fat diet by significantly increasing the activity of endogenous antioxidant enzymes in the liver and effectively inhibiting lipid peroxidation.

[0044] 10. Results of liver and intestinal inflammatory factor level tests The levels of inflammatory factors in liver and colon tissues were detected by ELISA, and the results (e.g.) Figure 9 , 10 As shown in the figure, compared with the blank control group (NC), the levels of key pro-inflammatory factors (IL-6, TNF-α, IL-1β) in the liver and colon tissues of high-fat diet model (HFD) mice were significantly increased. P<0.05, confirming that the high-fat diet successfully induced an inflammatory state in the hepatobiliary tissues. After PCPE1 intervention, except for the low-dose group (LP1), the levels of the above-mentioned inflammatory factors in all other intervention groups were significantly lower than those in the HFD group. P <0.05). In particular, high-dose PCPE1 (HP1) exhibited the strongest anti-inflammatory effect: in the liver, it restored IL-6 and IL-1β to normal levels (no significant difference compared to the NC group), and the levels of all three inflammatory factors were significantly lower than in the positive control group (POS); in the intestine, it also significantly reduced TNF-α and IL-6 levels (lower than the POS group) and restored TNF-α to normal. This indicates that high-dose PCPE1 can effectively alleviate systemic low-grade inflammation induced by a high-fat diet by significantly inhibiting the expression of pro-inflammatory cytokines in the hepatobiliary tissue.

[0045] 11. Mouse tissue pathological sections and staining Histopathological analysis was performed on the liver, colon, and epididymal adipose tissue of mice. Tissue samples were fixed in 10% neutral formalin, embedded in paraffin, and sectioned to a thickness of 4 µm. Hematoxylin and eosin (H&E), Oil Red O staining (liver), and alicin blue staining (colon) were performed, respectively. Stained sections were observed and images were acquired under an optical microscope (magnification: 200×).

[0046] The results are as follows Figure 11 As shown, H&E staining of epididymal adipose tissue revealed that, compared with the blank control group (NC), the high-fat diet model group (HFD) showed a significant increase in adipocyte volume, exhibiting adipocyte hypertrophy. Conversely, compared with the HFD group, the adipocyte size in each PCPE1 intervention group was significantly reduced in a dose-dependent manner, with the high-dose group (HP1) recovering to a level close to that of the NC group. This result is consistent with the aforementioned changes in the adipose tissue coefficient, confirming that high-dose PCPE1 can effectively improve the abnormal accumulation of adipose tissue induced by a high-fat diet.

[0047] Both H&E staining and Oil Red O staining results for the liver showed that hepatocytes in the HFD group exhibited numerous lipid vacuoles and lipid droplet deposition, indicating significant steatosis. After PCPE1 intervention, the number of lipid vacuoles and lipid droplets in hepatocytes was significantly reduced, with the HP1 group showing a recovery in hepatocyte morphology and lipid deposition area approaching the levels of the NC group. The active peptide PCPE1, especially its high dose (HP1), significantly improved high-fat diet-induced adipocyte hypertrophy and hepatic lipid deposition in a dose-dependent manner.

[0048] Example 5: Structural identification and lipid-lowering activity verification of bioactive peptides derived from Lactobacillus plantarum W8 cells. 1. Preparation of bioactive peptides <3 kDa derived from *Lactobacillus plantarum* cells The sample PCPE1 was used to extract active peptides from bacterial cells and retain the fraction with a value of <3 kDa.

[0049] 2. Peptide sequence analysis based on LC-MS / MS For mass spectrometry analysis, the PCPE1 fraction was first pretreated, including desalting and fractionation using a 3 kDa ultrafiltration tube. The resulting filtrate was then reduced with dithiothreitol (DTT) and alkylated with iodoacetamide (IAM), followed by desalting via a C18 stage-tip and vacuum drying. Peptide sequence analysis was performed using nanofluid chromatography-tandem mass spectrometry (LC-MS / MS). The chromatographic system was equipped with a C18 reversed-phase column, using a gradient elution with an acetonitrile-water solution containing formic acid as the mobile phase. Mass spectrometry was performed on a timsTOF Pro 2 mass spectrometer in data-dependent acquisition mode.

[0050] Raw mass spectrometry data were retrieved from a protein database targeting *Lactobacillus plantarum*. Cysteine ​​carbamylation was set as a fixed modification, while methionine oxidation and N-terminal acetylation of peptides were set as variable modifications. A non-specific enzyme digestion mode was employed. During the search, a precursor ion mass tolerance of 20 ppm and a fragment ion tolerance of 0.02 Da were set. The global false detection rate (FDR) was controlled to be less than 1% at both the protein and precursor ion levels to ensure the reliability of peptide identification results.

[0051] 3. Virtual screening of lipid-lowering peptides The measurement results are as follows Figure 12The results show that LC-MS / MS identification of the PCPE1 fraction yielded 6423 high-confidence peptides, from which 163 peptides with a content higher than 0.1% were selected as candidate peptides. The amino acid sequences of the selected target lipid-lowering peptides were used for 3D structure prediction and mapping using PEP-FOLD4. The predicted 3D structure files (PDB format) were downloaded for subsequent molecular docking analysis. 3D structure files of PL protein (PDB ID: 1LPB) and CE protein (PDB ID: 1F6W) were selected and downloaded from the Protein Data Bank database, ensuring that the selected PDB files contained the required complete protein structures. The PDB format peptides and target proteins were imported into Sailvina software. Necessary pretreatment steps were performed on the peptides, including water molecule removal, small molecule ligand removal, and hydrogen atom normalization. Hydrogen atoms were added to the proteins, and their conformation was optimized to ensure the correctness of the acceptor in the docking experiment. The pretreated peptides and receptor proteins were imported into AutoDock software to create docking boxes covering the entire protein. The docking center coordinates for the PL protein were set to -17.64, 15.24, 28.62 (x, y, z); for the CE protein, the coordinates were set to 31.14, 40.18, 41.84 (x, y, z). The docking box size for both proteins was set to 29×29×29. The optimal conformation was selected for molecular docking analysis. The interaction type between the active peptide and protein was evaluated using Discovery Studio 2019 software, and the results were visualized using PyMol software.

[0052] Molecular docking results are as follows ( Figure 13-16 The results show that both lipid-lowering peptides AP7 and TE8 can form stable complexes with their target proteins, pancreatic cholesterol esterase (CE) and pancreatic lipase (PL), but their binding modes differ fundamentally, determining their different affinity and selectivity characteristics. Both peptides bind to their target proteins through a multimodal network composed of hydrogen bonds, hydrophobic interactions, and electrostatic interactions. AP7 exhibits a highly target-dependent binding mode, while TE8 displays a broad-spectrum, high-affinity mode dominated by electrostatic interactions.

[0053] The binding site results are shown in Table 4. The binding of AP7 to CE mainly relies on the extensive hydrophobic interface formed by the conserved hydrophobic pocket composed of residues such as LEU110, LEU272, LEU274, and TRP227. This interaction is the main contributor to the binding free energy. Simultaneously, the directional hydrogen bond network formed with residues such as GLY106, ALA108, and TYR125 ensures the precise orientation and anchoring of the ligand at the active site. When binding to PL, this peptide forms up to eight hydrogen bonds with key catalytic residues of PL (such as ASP328 and ARG337) and surrounding polar residues, directly occupying the substrate binding channel, which supports its mechanism of action as a competitive inhibitor. Furthermore, hydrophobic interactions (PRO235, TYR369) and electrostatic attraction (with LYS367) act as key co-stabilizing factors, further consolidating the binding complex.

[0054] The ultra-high affinity of TE8 for both CE and PL primarily stems from the strong electrostatic interaction network formed by the peptide and the densely packed charged residues in their active pockets. This network, including HIS435 and ASP437 in CE binding and ARG337 and ASP387 in PL binding, constitutes the core contributor to the binding free energy. In CE binding, the electrostatic attraction is synergistically enhanced by surrounding hydrogen bonds and hydrophobic contacts, ensuring a stable binding. In PL binding, the strong electrostatic network further extends into a broad hydrogen bond network, enabling it to effectively occupy the substrate binding region and support its competitive inhibition mechanism.

[0055] Table 4 Molecular docking results Example 6: Chemical Synthesis and Activity Verification of Lipid-Lowering Peptides The peptides listed in Table 4 were chemically synthesized by Nanjing Peptide Valley Biotechnology Co., Ltd. (Nanjing, China) using a solid-phase synthesis method. The purity (≥95%) of the synthesized peptides was confirmed by high-performance liquid chromatography (HPLC), and the molecular weight was determined by mass spectrometry (MS). The synthesized peptides were stored in powder form at -80°C. The peptide powder was resuspended in deionized water before use.

[0056] The inhibition rates of AP7 and TE8 on pancreatic lipase (PL) and pancreatic cholesterol esterase (CE) were determined using the same method as in Example 2, where the enzyme activity inhibition rate was calculated according to the formula.

[0057] Table 5 Enzyme inhibition rate of lipid-lowering peptides polypeptide name Inhibition rate of pancreatic lipase (PL) / % Inhibition rate of pancreatic cholesterol esterase (CE) / % AP7 63.33% ± 4.77 56.91%± 4.05 TE8 63.98% ± 5.05 43.19%± 3.98 The peptides AP7 and TE8 provided in this invention are both excellent lipid-lowering peptides with both high efficiency and multi-target inhibitory properties. As shown in Table 5, peptides AP7 and TE8 exhibit significant inhibitory activity against both pancreatic lipase (PL) and pancreatic cholesterol esterase (CE), and this inhibitory effect is concentration-dependent. Specifically, the inhibition rates of peptides AP7 and TE8 against PL are as high as 63.33% and 63.98%, respectively, proving that both are highly efficient pancreatic lipase inhibitors. Simultaneously, both also show clear inhibitory potential against CE, with inhibition rates reaching 56.91% and 43.19%, respectively, with peptide AP7 showing more prominent inhibitory activity against CE. Peptides AP7 and TE8 can effectively block the lipid absorption process by synergistically inhibiting key enzymes in the digestion and absorption of dietary fat and cholesterol in the intestine. Therefore, peptides AP7 and TE8 together constitute the core active ingredients for achieving the lipid-lowering effect of this invention, providing an important material basis and application prospect for the development of multi-target lipid-lowering functional products.

Claims

1. A novel lipid-lowering peptide derived from probiotic cells, characterized in that, The lipid-lowering peptide is AP7 or TE8, with the amino acid sequence of AP7 being APGFGDR and the amino acid sequence of TE8 being TESGAFGR.

2. The novel lipid-lowering peptide derived from probiotic cells according to claim 1, characterized in that, The lipid-lowering peptide was extracted and isolated from the bacterial cells of Lactobacillus plantarum W8, which is deposited at the China General Microbiological Culture Collection Center with accession number CGMCC No. 31521 and deposited on August 1, 2024.

3. The novel lipid-lowering peptide derived from probiotic cells according to claim 2, characterized in that, Lactobacillus plantarum W8 was isolated from fermented soybean paste.

4. The novel lipid-lowering peptide derived from probiotic cells according to claim 1, characterized in that, The lipid-lowering peptide is derived from bacterial cell fragments and has a molecular weight of less than 3 kDa.

5. The application of the novel lipid-lowering peptide derived from probiotic cells as described in claim 1, characterized in that, Used to prepare products that improve lipid metabolism disorders.

6. The application of the novel lipid-lowering peptide derived from probiotic cells according to claim 5, characterized in that, The improvement of lipid metabolism disorders includes one or more of the following: binding bile salts, inhibiting cholesterol micelle formation, reducing serum total cholesterol, reducing serum triglycerides, reducing serum low-density lipoprotein cholesterol, increasing serum high-density lipoprotein cholesterol, reducing hepatic lipid deposition, alleviating hepatic steatosis, reducing weight gain, reducing body fat accumulation, improving oxidative stress, or inhibiting inflammation.

7. The application of the novel lipid-lowering peptide derived from probiotic cells as described in claim 1, characterized in that, Used to prepare products that inhibit pancreatic lipase and / or pancreatic cholesterol esterase.

8. A product for improving lipid metabolism disorders or inhibiting pancreatic lipase and / or pancreatic cholesterol esterase, characterized in that, The product contains the lipid-lowering peptide as described in claim 1.

9. The product according to claim 8, characterized in that, The product is a medicine, health product, or functional food.